Industrial Doctorate Centre: Systems Approaches to Biomedical Science

工业博士中心：生物医学科学的系统方法

• 批准号: EP/G037280/1
• 负责人: David Gavaghan
• 金额: $ 844.5万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Training Grant
• 财政年份: 2009
• 资助国家: 英国
• 起止时间: 2009 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FG037280%2F1
• 关键词: Industrial; Doctorate; Centre; Systems; Approaches

The goal of the proposed Oxford Industrial Doctorate in Systems Approaches to Biomedical Science is to ensure that the UK has a strong pipeline of future innovators and research leaders in the pharmaceutical, biomedical, biotechnology, and biomedically-related IT sectors. It will build on the track record and model of inter-disciplinary scientific training of the two existing DTCs in Oxford (at the Life Sciences Interface and in Systems Biology), and of our existing Industrial Doctorate pilot scheme, to provide a comprehensive industrial research training programme, tailored to the needs of each individual student, and will engage with internationally leading industrial partners and academic groups drawn from across the spectrum of EPSRC's healthcare-related programmes. Graduates from the IDC programme will receive extensive exposure to the industrial context of their research in both the taught programme and in their industry-based research projects. This will allow them to develop the skills in project management, strategic planning, leadership, team working, commercial awareness, and problem solving that will be required to translate innovations in basic and medical science into commercial product development.The proposal has very strong support from across the relevant industry sectors (pharmaceutical, biomedical and imaging, health-related IT and biotechnology). The 13 companies supporting this proposal are: GE Healthcare (Dr Jonathan Allis, Vice President for Technology); GSK (Professor Paul Matthews, Vice President, Imaging and Head, GSK Clinical Imaging Centre); AstraZeneca (Dr Andy Hargreaves, Director, Advanced Science and Technology Lab); Roche (Dr Bryn Roberts, Global Head of Group Research); Novartis (Dr Ulrich Hummel, Unit Head, Structural Sciences); Pfizer (Ian Machin, Director Pain Discovery Biology); Siemens Molecular Imaging (Dr. Jrme Declerck, Head of Science and Technology), Microsoft Research (Prof Stephen Emmott , Director of External Research), Philips (Dr Lothar Spies, Head of Digital Imaging); Fujitsu European Laboratory (Dr Ross Nobes, Head of Computational Biology), UCB Celltech (Dr Jiye Shi); Inhibox (Dr Paul Finn); and Summit (Richard Vickers, Drug Discovery). Full details of the levels of support to be provided to the IDC by each of these companies are given in the attached letters of support from each of the representatives listed above. Several of these companies will be directly involved in the teaching programme of the proposed IDC.Producing these industrial scientists is of paramount importance if the UK is to remain at the forefront of the biotechnology, biomedical and pharmaceutical sectors. Current economic conditions are resulting in financial pressures across these sectors, but future innovation and product development requires that the training of these future generations of scientists commences now. EPSRC support is therefore vital. Similarly, the interdisciplinary nature of the proposed training and research programmes necessitate a critical mass of students within the training programme who can support and learn from one another, and the overall goals of the IDC simply could not be met by the standard PhD training route.

拟议的牛津工业博士学位系统方法生物医学科学的目标是确保英国在制药，生物医学，生物技术和生物医学相关的IT部门拥有强大的未来创新者和研究领导者管道。它将建立在牛津两个现有的DTCs的跨学科科学培训的记录和模式的基础上（在生命科学接口和系统生物学），以及我们现有的工业博士试点计划，提供一个全面的工业研究培训计划，针对每个学生的需要，并将与国际领先的工业合作伙伴和来自EPSRC医疗保健相关项目的学术团体合作。IDC计划的毕业生将在教学计划和基于行业的研究项目中广泛接触他们的研究的工业背景。这将使他们能够发展项目管理，战略规划，领导能力，团队合作，商业意识和解决问题的能力，这将需要将基础和医学科学的创新转化为商业产品开发。该提案得到了相关行业部门（制药，生物医学和成像，与健康相关的IT和生物技术）的大力支持。支持这一提议的13家公司是：通用电气医疗（Jonathan Allis博士，技术副总裁）; GSK（Paul马修斯教授，GSK临床影像中心影像副总裁兼负责人）;阿斯利康（Andy Hargreaves博士，高级科学和技术实验室主任）;罗氏（Bryn Roberts博士，集团研究全球负责人）;诺华（Ulrich Hummel博士，结构科学部门负责人）;辉瑞（Ian Machin，疼痛发现生物学主任）;西门子分子成像（Jrme Declerck博士，科学和技术负责人），微软研究院（外部研究总监Stephen Emmott教授），飞利浦（数字成像主管Lothar Spies博士）;富士通欧洲实验室（Ross Nobes博士，计算生物学负责人），UCB Celltech（Jiye Shi博士）; Inhibox（Paul Finn博士）;和Summit（Richard Vickers，药物发现）。这些公司中的每一个公司将向国际数据中心提供的支助水平的详细情况载于所附的上述每一位代表的支助信。其中几家公司将直接参与拟议的国际数据中心的教学计划。如果英国要保持在生物技术、生物医学和制药领域的领先地位，培养这些工业科学家至关重要。目前的经济状况导致这些部门的财政压力，但未来的创新和产品开发要求现在就开始培训这些未来的科学家。因此，EPSRC的支持至关重要。同样，拟议的培训和研究方案的跨学科性质要求培训方案中有足够数量的学生，他们可以相互支持和学习，而国际数据中心的总体目标根本不可能通过标准的博士培训途径来实现。